SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

ALTUVIIIO

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (US)
Time to market
Already approved and marketed in the U.S. (first FDA approval Feb 22, 2023); sold commercially
Why 3/10
ALTUVIIIO was already FDA-approved (February 22-23, 2023) and is commercializing with no pending regulatory decision or pivotal readout scheduled in the next ~12 months, SecBot's local data shows no upcoming FDA catalyst for SNY, and it is a small slice of a roughly $109B company, so no hard dated binary exists to drive a large share-price move.
Actionable Insight NEUTRAL

For SNY holders, ALTUVIIIO is a genuine growth product but not a stock-moving event: the approval binary passed in Feb 2023, and Sanofi's share-price catalysts live elsewhere (e.g., Dupixent momentum and a venglustat FDA decision reportedly targeted Nov 25, 2026). Watch quarterly Sanofi disclosures for ALTUVIIIO sales growth and the pending presentation of a completed Phase 3 joint-health study (NCT05817812, results not yet posted) as the main drug-specific updates.

Price Chart

Loading chart...

Executive Summary

ALTUVIIIO (efanesoctocog alfa, formerly BIVV001) is Sanofi's first-in-class once-weekly factor VIII replacement therapy for hemophilia A, FDA-approved Feb 22-23, 2023 for adults and children, covering routine prophylaxis, on-demand bleeding control, and surgery. It delivers ~3-4x longer half-life than standard/extended half-life factor VIII products and is commercializing with Sobi as partner. The drug is a real growth contributor for Sanofi (a ~$109B company that grew H1 2026 net sales +11.1% reported / +15.7% CER), but the approval catalyst has passed, competition is stiff, and no ALTUVIIIO-specific binary is scheduled, hence a neutral investor read at the SNY level.

How It Works

Hemophilia A patients lack working clotting factor VIII, so they bleed easily. ALTUVIIIO is an engineered version of factor VIII (fused to pieces of the von Willebrand factor protein plus 'Fc' and 'XTEN' segments) that keeps working on its own in the bloodstream instead of depending on the body's natural VWF. That gives it a roughly 3-4x longer half-life than standard factor VIII, so patients need only one injection a week instead of several, and it keeps clotting-factor levels high enough to nearly eliminate bleeds.

Trial Status

Approved in the US for hemophilia A (adults and children) in Feb 2023 for prophylaxis, on-demand treatment, and surgery; a Phase 3 study of once-weekly efanesoctocog alfa on physical activity and joint health in severe hemophilia A (NCT05817812, Sobi-sponsored) completed June 2, 2026 with results not yet posted.

The Two-Sided Case

▲ Bull Case4
First-in-class 'high sustained' factor VIII: engineered to work independently of endogenous von Willebrand factor, with a reported 3-4x longer half-life than standard and extended half-life (EHL) FVIII products, enabling once-weekly dosing (Haematologica article).
Broad US label: approved for adults AND children with hemophilia A for routine prophylaxis, on-demand treatment/control of bleeding, and perioperative (surgery) management (FDA page; Sanofi press release).
Commercial momentum: ALTUVIIIO is named among Sanofi's product portfolio in H1 2026 results, in which Sanofi reported net sales of €22,106M (+11.1% reported, +15.7% CER) and raised FY2026 guidance, with 'new launches' a stated growth driver (SEC 6-K analysis, Jul 30, 2026).
Co-developed with Sobi, which has its own global hemophilia franchise and co-announced the US approval, expanding commercial reach beyond the US (Sobi press release).
▼ Bear Case4
The defining binary already passed: US approval happened Feb 2023, and SecBot's local data shows no pending FDA decision or pivotal readout for ALTUVIIIO, so there is no scheduled event likely to move SNY shares on this drug alone.
Concentration risk is minimal but two-way: at a roughly $109B market cap, ALTUVIIIO is one of several 'new launch' contributors while Dupixent (€9,324M H1 2026, +34.4% CER) dominates, drug-specific news is diluted in the SNY story, which in H1 2026 was dominated by a €952M amlitelimab impairment and pipeline setbacks.
Competitive market: ALTUVIIIO's edge is defined against standard and EHL factor VIII products (Haematologica), and hemophilia A prophylaxis is a crowded, payer-sensitive category where rivals include subcutaneous and longer-acting alternatives; market-share and reimbursement outcomes are unproven over time.
The one drug-specific data item, a Sobi-sponsored Phase 3 joint-health study (NCT05817812) that completed June 2026, has results not yet posted, and a data presentation is not a binary catalyst.

Upcoming Catalysts

  • Publication/presentation of results from the completed Phase 3 physical-activity and joint-health study (NCT05817812), timing not yet announced
  • Quarterly Sanofi earnings disclosures of ALTUVIIIO sales (H2 2026 / full-year report), growth updates, not binary events
  • No FDA PDUFA, advisory committee, or pivotal readout for ALTUVIIIO scheduled in SecBot's local 30-90 day catalyst window

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 15

Hover a chip for the title
1 sanofi.com2 fda.gov3 fda.gov4 drugs.com5 en.wikipedia.org6 sobi.com7 hemophilianewstoday.com8 hemophilianewstoday.com9 bleeding.org10 haematologica.org11 nejm.org12 sanofimarketaccess.com13 sanofimarketaccess.com14 novapharmanews.com15 sec.gov